Inactive Instrument

Lannett Company, Inc.

LCI

US5160122009

Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023

May 15, 2023 at 04:16 pm EDT

Lannett Company, Inc. reported earnings results for the third quarter and nine months ended March 31, 2023. For the third quarter, the company reported sales was USD 80.51 million compared to USD 78.36 million a year ago. Net loss was USD 101.47 million compared to USD 34.9 million a year ago. Basic loss per share from continuing operations was USD 9.84 compared to USD 3.45 a year ago. Diluted loss per share from continuing operations was USD 9.84 compared to USD 3.45 a year ago.
For the nine months, sales was USD 236.48 million compared to USD 266.39 million a year ago. Net loss was USD 165.8 million compared to USD 138.33 million a year ago. Basic loss per share from continuing operations was USD 16.13 compared to USD 13.74 a year ago. Diluted loss per share from continuing operations was USD 16.13 compared to USD 13.74 a year ago.

Latest news about Lannett Company, Inc.

Lannett Company, Inc. Emerges as a Private Company with New Board of Directors	23-06-16	CI
Lannett Company, Inc. Emerged from Bankruptcy	23-06-16	CI
First Amended Prepackaged Joint Plan of Reorganization and Disclosure Statement Approved for Lannett Company, Inc.	23-06-08	CI
First Amended Prepackaged Joint Reorganization Plan Filed by Lannett Company, Inc.	23-06-05	CI
Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-15	CI
Motion for Joint Administration Approved for Lannett Company, Inc.	23-05-04	CI
Combined Hearing for Disclosure Statement and Plan Approved for Lannett Company, Inc.	23-05-04	CI
Global markets live: Ford, AMD, Starbucks, Estee Lauder, CVS Health....	23-05-03
Motion for Joint Administration Filed by Lannett Company, Inc.	23-05-03	CI
Prepackaged Joint Reorganization Plan and Disclosure Statement Filed by Lannett Company, Inc.	23-05-02	CI
Lannett Company, Inc. Filed for Bankruptcy	23-05-02	CI
Lannett Company, Inc.(OTCPK:LCIN) dropped from S&P TMI Index	23-04-25	CI
John Kozlowski Leaves Lannett Company, Inc. as Principal Accounting Officer, Effective May 16, 2023	23-04-14	CI
John Kozlowski Leaves Lannett Company, Inc. as Chief Financial Officer, Effective May 16, 2023	23-04-14	CI
Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial	23-04-04	CI
Top Premarket Gainers	23-02-02	MT
Transcript : Lannett Company, Inc., Q2 2023 Earnings Call, Feb 01, 2023	23-02-01
Earnings Flash (LCI) LANNETT COMPANY Reports Q2 Revenue $80.9M	23-02-01	MT
Earnings Flash (LCI) LANNETT COMPANY Posts Q2 Loss $-0.34	23-02-01	MT
Lannett Company, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-01	CI
Lannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022	23-02-01	CI
Lannett Company, Inc. Raises Earnings Guidance for the Fiscal Year 2023	23-02-01	CI
Lannett to Implement 1-for-4 Reverse Stock Split	23-01-26	MT
Lannett Company Provides Development Update on Biosimilar Insulin Products	23-01-04	CI
Jeffrey Farber Announces Not to Stand for the Re-Election to the Board of Lannett Company, Inc	22-11-29	CI

Chart Lannett Company, Inc.

Duration

Period

More charts

Company Profile

Lannett Company, Inc. is engaged in the development, manufacturing, marketing and distribution of generic versions of brand pharmaceutical products. The Company markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company's product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals